Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients
12:33pm, Tuesday, 10'th Mar 2026
The FDA underscored cases including two deaths and a suicide linked to patients taking semaglutide, which Novo markets as Ozempic and Wegovy.
Should Value Investors Buy Global Partners (GLP) Stock?
10:40am, Tuesday, 10'th Mar 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy
07:30am, Tuesday, 10'th Mar 2026
NEWPORT BEACH, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the initiation of a preclinical study for EL-32, an engine
- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses. - ASC
Lindt says GLP-1 users are eating more chocolate, not less
04:11am, Tuesday, 10'th Mar 2026
Chocolate sales are rising faster among U.S. users of GLP-1 weight-loss drugs than in the rest of the population, Swiss chocolatier Lindt & Spruengli said on Tuesday, citing data that went again
Hims & Hers: Not Selling Yet
05:51pm, Monday, 09'th Mar 2026
Hims & Hers shares surged over 40% after renewing its partnership with Novo Nordisk to sell GLP-1 weight-loss drugs. The new deal reverses last year's public fallout, restoring a key catalyst for Hims
Is Global Partners (GLP) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:45pm, Monday, 09'th Mar 2026
Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.
Global Partners (GLP) Upgraded to Buy: Here's Why
01:00pm, Monday, 09'th Mar 2026
Global Partners (GLP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Omada Health: GLP-1-Focused Telehealth Platform Users May Feel They Can Do Without
08:15am, Monday, 09'th Mar 2026
Omada Health targets enterprise GLP-1 companion care, leveraging its platform to manage high employer demand for GLP-1 drugs. 2025 revenues grew 53% to $260M; 2026 guidance implies 22% topline growth
Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM)
07:40am, Monday, 09'th Mar 2026
GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301 Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs' primary sid
Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce
10:56am, Saturday, 07'th Mar 2026
In a dramatic reversal of fortune, Hims & Hers Health ( NYSE:HIMS ) has been rescued by the very company that nearly sank it.
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
06:05pm, Friday, 06'th Mar 2026
Novo Nordisk shares look cheap, but execution and management changes weigh on investor confidence. Eli Lilly's stronger GLP-1 growth and consistency support its premium versus Novo's conditional value
Omada Health Announces GLP-1 Flex Care, Giving Employers a New, Flexible Path to Support Obesity Care
04:07pm, Thursday, 05'th Mar 2026
SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first provider of between-visit care, today announced GLP-1 Flex Care, a new offering that will support emplo
GLP-1 drugs protect against new or worsening addictions, large study shows
06:36pm, Wednesday, 04'th Mar 2026
Ozempic, Mounjaro and other GLP-1 drugs for diabetes can prevent the formation of new substance use disorders and alleviate existing addictions, according to findings from a large study of U.S. mil
Midstream Energy: Relative Favorability
01:56am, Wednesday, 04'th Mar 2026
Twenty-nine midstream energy companies were evaluated on a relative favorability matrix with factors representing yield, yield coverage, valuation, profitability, growth, and leverage. Based on this a
